2018 Certificate Schedule
Psychedelic Therapies and Research Certficate
Hybrid Residential and Online Curriculum:
The 180-hour 2018 certificate program includes 6 meetings: 4 long weekends in the San Francisco Bay Area at CIIS; a 7-day residential Bay Area retreat in June; a 3-day Bay Area residential retreat in September; 30 hours of mentoring and volunteer work; and 25 online hours of review of instructional videos of the didactic modules. Thus, this well-organized hybrid academic program entails 125 hours of residential study in the San Francisco Bay Area and 55 hours of study and practice at home. Such a hybrid program enables trainees from outside of California to more readily participate in the training program. See the 2018 exact schedule of 6 meetings in the section below.
The learning environment will be in the form of lectures, small group discussion, experiential learning (e.g., Holotropic Breathwork, role-play, guided imagery, expressive arts, journaling) and applied work in clinical and therapeutic settings. Classes begin at the end of March 2018. We meet until the end of June, then have the summer off for volunteer work and online study, and meet again from September through November 2018. The first retreat in June, 2018 at the Marconi Conference Center in Marshall, CA. is one of the modules of the MAPS training program for therapist guides. The MAPS founding trainers, Dr. Michael Mithoefer and Annie Mithoefer, RN, will be our June retreat's expert instructors. The second retreat in September will be focused on sessions of Holotropic Breathwork with lead teacher Diane Haug from the Grof Transpersonal Training.
The 2018 Schedule for the Certificate:
|March 23rd, 24th, and 25th:||Welcome Weekend at CIIS|
|May 4th, 5th, and 6th:||Weekend at CIIS|
|June 24th - 30th Retreat:||With the Mithoefers of MAPS at a retreat center near San Francisco|
|September 14th, 15th, and 16th Retreat:||At a retreat center near San Francisco|
|October 26th, 27th, and 28th:||Weekend at CIIS|
|November 30th, December 1st and 2nd:||Weekend at CIIS and Graduation|
The Daily Schedule for the Four Weekends at CIIS:
Fridays from 4 pm. to 7 pm.
Saturdays from 10 am. to 5 pm. and 7 pm. to 9 pm.
Sundays from 10 am. to 3 pm.
The Daily Schedules for the Two Residential Training Retreats:
The June 7-day Retreat at a residential center near San Francisco:
Begins Sunday, June 24th, at 1 pm. and ends on Saturday, June 30th at 2 pm.
The September 3-day Retreat at a residential center near San Francisco:
Begins Friday, September 16th at 1 pm. and ends on Sunday, September 18th at 4 pm.
These are the assigned dates for the certificate classes and the exact schedule with the teachers will be announced shortly.
Download the program and application 2018 Information Packet.
THE CERTIFICATE PROGRAM FACULTY BIOS:
Click "MORE" button below for the FACULTY BIOS.
Planned 2018 Faculty for the Certificate Program
Allan Badiner is a contributing editor at Tricycle magazine, and the editor of the new edition of Zig Zag Zen: Buddhism and Psychedelics. He also edited the books Dharma Gaia: A Harvest in Buddhism and Ecology and Mindfulness in the Marketplace and his written work appears in other books including Dharma Family Treasures, Meeting the Buddha, Ecological Responsibility: A Dialogue with Buddhism, and The Buddha and the Terrorist. Allan holds a master's degree from the College of Buddhist Studies in Los Angeles and serves on the boards of Rainforest Action Network and Project CBD. For two years, Allan taught classes at CIIS on Buddhism and modern problems. He is currently working on a book about dietary cannabinoids.
Anthony P. Bossis, PhD, is a clinical psychologist and Clinical Assistant Professor of Psychiatry at New York University School of Medicine. He was director of palliative care research, co-principal investigator, and a session guide for the NYU Psilocybin Cancer Anxiety Study and is the Project Director and primary session guide for the NYU Psilocybin Religious Leaders Study, a clinical trial evaluating the effects of a psilocybin-facilitated mystical experience upon religious leaders. Dr. Bossis is a clinical supervisor of psychotherapy training at Bellevue Hospital, is the co-founder and former Co-Director of the Palliative Care Service, and served on the NYU Chaplains Clinical Pastoral Education Advisory Committee. He has a longstanding interest in comparative religion, consciousness research, and the interface of psychology and spirituality. He maintains a private psychotherapy practice in New York City.
Karen M. Cooper, RN, BSN, MA, was Lead Guide and Clinical Research Nurse for the University of Wisconsin's Psilocybin Pharmacokinetic Study, and served as the study trainer with the Usona Institute. She currently enjoys serving as mentor, guest faculty, and member of the Advisory Board for the Certificate in Psychedelic Therapies and Research program at CIIS, and is the Project Manager and Co-therapist for the anticipated MAPS MDMA-assisted Phase III clinical trial at the clinical study site in Fort Collins, Colorado. She is a student of meditation and yoga, and a licensed bodyworker and massage therapist. Karen finds that an eclectic nursing background working with patients ranging from prenatal and neonatal care to end-of-life hospice lends well to her love for lifelong learning of science, consciousness, psychology, society, and spirituality. Her interests include learning about Colorado native plants, herbs, and food as medicine; biking and hiking; ecstatic dance; painting; meditation; exploring the natural beauty of her new home in northern Colorado with her husband Dan Muller.
Mary Cosimano, MSW, is currently with the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine. Ms. Cosimano has served as study guide and research coordinator for psilocybin studies for over 15 years. During that time, she has been a lead session guide for six studies and has conducted over 350 sessions. She has trained post-doctoral fellows, research assistants, and interns as assistant guides. She has administered the psychological evaluations for psilocybin studies as well as many other studies in the Behavioral Biology Research Unit. Ms. Cosimano has 15 years of experience with direct patient care as a hospice volunteer. In addition to her work with the psilocybin studies, she has been involved in the salvia divinorum, dextromethorphan, and club drug studies conducted at Johns Hopkins
Nicholas Cozzi, PhD, is a scientist and educator at the University of Wisconsin, Madison School of Medicine and Public Health. His background and training is in pharmacology, chemistry, and neuroscience. Dr. Cozzi's research involves the design, chemical synthesis, and pharmacological testing of substances with central nervous system activity, especially those with psychedelic, antidepressant, or psychostimulant effects. Dr. Cozzi is internationally recognized for his work in these areas. Nick teaches medical pharmacology at the UW School of Medicine and Public Health and the UW School of Pharmacy. He is a frequent guest lecturer at other academic institutions around the United States. Dr. Cozzi has received several teaching and research awards, including a Distinguished Basic Science Teaching Award from the University of Wisconsin, Madison and a prestigious NARSAD Award from the Brain and Behavior Research Foundation for his studies involving the serotonin uptake transporter. His research has also been supported by grants from the National Institutes of Health. Dr. Cozzi is a Senior Research Scientist at the Usona Institute and a consultant for legal, industrial, and government clients.
Alicia Danforth, PhD, is a clinical psychologist in private practice in Los Gatos, California. Since 2006, she has worked in clinical research at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center on clinical studies for adults with anxiety related to advanced-stage cancer and with autistic adults who experience social anxiety. She is currently a lead clinician and supervisor for a clinical trial at UCSF for psychological distress in long-term survivors of HIV/AIDS. She attended the Institute of Transpersonal Psychology, where she co-developed and taught the first graduate-level course on psychedelic theory, research, and clinical considerations for therapists and researchers in training.
Rick Doblin, PhD, is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a 34-year follow-up study to Timothy Leary's Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston.
Amy Emerson, BS, earned her BS in genetics and cell biology from Washington State University in 1992. Prior to her work at the Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MPBC) she worked in clinical development and research beginning in 1993. Amy's previous experience is in the fields of immunology (Applied Immune Sciences), oncology (RPR), and vaccine development (Chiron and Novartis). Amy worked with MAPS as a volunteer starting in 2003 facilitating the development of the MDMA clinical program. In 2009, she began managing the Clinical Research group at MAPS. She is currently the Executive Director and Director of Clinical Research of MPBC.
George Goldsmith, MA, holds a bachelor's degree in cognitive psychology from the University of Rochester, and a master's degree in clinical psychology from the University of Connecticut. He has founded several technology companies - including The Human Interface Group, TomorrowLab, and Tapestry Networks - and served as a senior advisor to McKinsey & Company before founding COMPASS, a multi-tiered medical research foundation. COMPASS leads mental health policy dialogues; funds new treatment research protocols, including research on the clinical applications of empathogens and entheogens; and forms strategic partnerships to bring research findings into clinical, regulatory, and legislative settings.
Charles Grob, MD, is Professor of Psychiatry and Pediatrics at the UCLA School of Medicine and the Director of the Division of Child and Adolescent Psychiatry at the Harbor-UCLA Medical Center. His longstanding interest in the history of psychiatric research with hallucinogens has generated an impressive history of conference presentations and publications in leading medical and psychiatric journals. Dr. Grob received the first FDA approval to carry out human research with 3,4-methylenedioxymethamphetamine (MDMA) in the early 1990s. He has collaborated with Drs. Dennis McKenna and Jace Callaway on the Hoasca Project, research that explored the biochemical, physiological, and psychological impacts of long-term ayahuasca use in Brazil. From 2004 to 2008, Dr. Grob conduced an FDA-approved study examining the effects of psilocybin in advanced-stage cancer patients with severe anxiety. Results from this trial were published in the Archives of General Psychiatry in 2011. Dr. Grob is currently conducting a pilot study of an MDMA treatment model for autistic adults with social anxiety. He is a founding board member of the Heffter Research Institute. Dr. Grob is the editor of Hallucinogens: A Reader, and the co-editor with Dr. Roger Walsh of Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics.
Stanislav Grof, MD, is a psychiatrist with more than 50 years of experience in researching non-ordinary states of consciousness induced by psychedelic substances and various non-pharmacological methods. He is professor emeritus at CIIS, conducts professional training programs in Holotropic Breathwork and transpersonal psychology, and gives lectures and seminars worldwide. He is one of the founders and chief theoreticians of transpersonal psychology and the founding president of the International Transpersonal Association. Dr. Grof has received the prestigious Vision 97 award from the Dagmar and Václav Havel Foundation in Prague and the Thomas R. Verny Award for his pivotal contributions to pre- and perinatal psychology. He has published more than 150 papers in professional journals and the books Realms of the Human Unconscious, Beyond the Brain, LSD Psychotherapy, The Cosmic Game, Psychology of the Future, When the Impossible Happens, The Ultimate Journey, Healing Our Deepest Wounds, Spiritual Emergency, The Stormy Search for the Self, and Holotropic Breathwork (the last three with Christina Grof).
George Greer, MD, is a psychiatrist who conducted over 100 therapeutic sessions with MDMA for 80 individuals from 1980 to 1985 with his wife, psychiatric nurse Requa Tolbert Greer. Their review of this work remains the largest published study on the therapeutic use of MDMA. Dr. Greer is a Distinguished Life Fellow of the American Psychiatric Association and Past President of the Psychiatric Medical Association of New Mexico. He was also the Clinical Director of Mental Health Services for the New Mexico Corrections Department during the 1990s. He a co-Founder of the Heffter Research Institute and has been the organization's Medical Director since 1998.
Jeffrey Guss, MD is a psychiatrist and psychoanalyst with specialization in addictive disorders and psychotherapy. He is Co-Principal Investigator and the Director of Therapist Training for the NYU Psilocybin Cancer Anxiety Project. Dr. Guss is developing a model for training therapists for cancer related therapy trials, as well as imagining clinical practice with psilocybin-assisted therapy. He maintains a psychotherapy based practice in New York City and is a graduate of the NYU Postdoctoral Program in Psychotherapy and Psychoanalysis.
Diane Haug, MA, LPCC, is a licensed therapist and a senior member of the Grof Transpersonal Training (GTT) staff. Her background includes a decade of working with adults and children dealing with life-threatening illness. Over the last 25 years, she has been deeply involved with transpersonal psychology and the international breathwork community, leading Grof training events in Scandinavia, Russia, Ukraine, South America, and Europe. Diane has taught GTT training modules including The Practice of Holotropic Breathwork, Music and Transcendence, The Language of the Soul: The Art and Practice of Integrating Deep Inner Experience, Shamanism: An Exploration of Traditional Wisdom, Living with Dying, and The Psychedelic Experience: Promises and Perils. Diane is an adjunct faculty member at Southwestern College, a transpersonally oriented graduate school in Santa Fe, New Mexico. She serves as the Executive Director of the Ocamora Retreat Center in Ocate, New Mexico, and maintains a practice that includes both private and group work.
Bob Jesse is convener of the Council on Spiritual Practices (CSP). Through CSP, he was instrumental in forming the psilocybin research team at Johns Hopkins University. As one of the team's co-investigators, Mr. Jesse co-authored its first paper, "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance," published in 2006. He now serves on the board of Usona Institute and is an advisor to CIIS. In 2005, he led the writing of an amicus brief to the U.S. Supreme Court in a key religious liberty case that was decided 8-0 in favor of the U.S. branch of the Brazilian church, the União do Vegetal. Prior to CSP, Mr. Jesse applied his training in computer science and electrical engineering at various information technology companies, including AT&T Bell Labs and Oracle Corporation.
Mariavittoria Mangini, PhD, FNP has written extensively on the impact of psychedelic experiences in shaping the lives of her contemporaries, and has worked closely with many of the most distinguished investigators in this field. She is a founder of the Women's Visionary Council, a nonprofit organization that supports investigations into non-ordinary forms of consciousness and organizes gatherings of researchers, healers, artists, and activists whose work explores these states. Her long history with the Haight Ashbury Free Clinic includes having been a barefoot patient, a lead clinician in the medical section, and the chair of the Board of Directors - all in the same lifetime. She has been a Family Nurse Midwife for 35 years, and has been in primary care practice with Frank Lucido, MD, one of the pioneers of the medical cannabis movement, for 24 years. Their practice was one of the first to implement the California Compassionate Use Act of 1996, the first state medical cannabis initiative. Her current project is the development of a thanatology program for the study of death and dying.
Gabor Maté, MD, is a medical doctor recently retired from active practice. He was a family physician for two decades and for seven years he served as Medical Coordinator of the Palliative Care Unit at Vancouver Hospital. For twelve years he worked in Vancouver's Downtown Eastside with patients challenged by hardcore addiction, mental illness, HIV, and related conditions. For two years he was the onsite physician at Vancouver's unique Supervised Injection Site, North America's only such facility. He is internationally known for his work on mind/body unity in health and illness, on attention deficit disorder and other childhood developmental issues, and his breakthrough analysis of addiction as a psychophysiological response to childhood trauma and emotional loss. He is the author of four bestselling books published in twenty languages on five continents, including When The Body Says No: Exploring the Stress-Disease Connection and the award winning In the Realm of Hungry Ghosts: Close Encounters With Addiction. Gabor is the recipient of an Outstanding Alumnus Award from Simon Fraser University and an Honorary Degree of Law from the University of Northern British Columbia, among other awards. He frequently addresses professional and lay audiences in North America on childhood development and parenting, physical and mental health and wellness, and addiction. He is an adjunct professor in the Criminology department at Simon Fraser University. His next book, Toxic Culture: Trauma, Illness, and Healing in a World of Materialism will be published in 2016.
Natalie Metz, ND, is a licensed naturopathic doctor, herbalist, and core faculty member in the Integrative Health Studies department at CIIS. She has a private practice in Oakland where she focuses on digestive and hormonal wellness with the support of plant medicine, homeopathy, and diet and lifestyle interventions. She is a lifelong student of dance, a lover of art, travel, and all things purple, and enjoys sharing her passion for life with the world. Please visit www.drnataliemetz.com for more information.
Ralph Metzner, PhD, is a recognized pioneer in psychological, philosophical, and cross-cultural studies of consciousness and its transformations. He collaborated with Leary and Alpert in classic studies of psychedelics at Harvard University in the 1960s, co-authored The Psychedelic Experience, and was editor of The Psychedelic Review. He is a psychotherapist and professor emeritus at CIIS, where he was also the Academic Dean for ten years in the 1980s. His books include The Unfolding Self, The Well of Remembrance, Green Psychology and most recently (2017) Ecology of Consciousness. He is the editor of two collections of essays on the pharmacology, anthropology, and phenomenology of ayahuasca and psilocybin mushrooms. He is also the president and co-founder of the Green Earth Foundation, dedicated to healing and harmonizing the relations between humanity and the Earth. His website is www.greenearthfound.org.
Annie Mithoefer, BSN, is a psychiatric nurse and Grof-certified Holotropic Breathwork practitioner who is also trained in Hakomi Therapy. She and her husband, Michael Mithoefer, have practiced in Charleston, South Carolina for 20 years using experiential methods of psychotherapy and self-exploration, including Holotropic Breathwork. They now focus on clinical research with MDMA-assisted psychotherapy for PTSD. They are co-therapists for MAPS-sponsored clinical trials, and they conduct training programs for other MAPS-sponsored researchers.
Michael Mithoefer, MD, is a psychiatrist who specializes in treatment of post-traumatic stress disorder (PTSD) with an emphasis on experiential methods of psychotherapy including Holotropic Breathwork and Internal Family Systems therapy. He and his wife, Annie Mithoefer, conduct MAPS-sponsored research into MDMA-assisted psychotherapy for PTSD. In 2008, they completed the first clinical trial of MDMA-assisted psychotherapy for people with treatment-resistant PTSD and are now conducting a similar study of military veterans, firefighters, and police officers with PTSD, as well as an FDA-approved study administering MDMA in a therapeutic setting to psychotherapists who have been trained to work in MDMA clinical trials. Michael is Medical Monitor for other MAPS-sponsored MDMA studies, and he and Annie conduct training for therapists who work in those trials. He is a Grof-certified Holotropic Breathwork practitioner, a certified Internal Family Systems therapist, and is board certified in psychiatry, emergency medicine, and internal medicine. Michael is Clinical Assistant Professor of Psychiatry at the Medical University of South Carolina.
Lia Mix, MS, MFT, holds a master's degree in counseling with a concentration in multicultural populations. Ms. Mix has worked in multiple behavioral health settings: foster care services, dual diagnosis outpatient care, workplace crisis response, and corporate consulting. She helped create industry-leading counseling and case management programs and has supported insurance benefit administration and design for newly adopted behavioral health treatments. Ms. Mix has provided consultation for key decision makers within a wide range of corporate, nonprofit, and governmental organizations and brokerage firms. Her current focus is autism spectrum disorders.
David E. Nichols, PhD is Adjunct Professor of Chemical Biology and Medicinal Chemistry at the Eshelman School of Pharmacy at UNC, Chapel Hill. Previously he held the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology and was a Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology at the Purdue University College of Pharmacy. He also was Adjunct Professor of Pharmacology and Toxicology at the Indiana University School of Medicine. He received his B.S. in chemistry from the University of Cincinnati in 1969, and a PhD in Medicinal Chemistry from the University of Iowa in 1973, followed by postdoctoral work in pharmacology, also at Iowa. He joined Purdue as an Assistant Professor in 1974 where he remained until his retirement in June 2012. He has published more than 300 scientific articles, is recognized as a leading authority on psychedelics, and is the founding president of the Heffter Research Institute.
Janis Phelps, PhD, is the founder and Director of the Certificate for Psychedelic-Assisted Therapies and Research. She is former Dean of Faculty for the CIIS School of Humanities and Social Sciences, a clinical psychologist and a marriage and family therapist. With 29 years of experience as teaching in university graduate psychology departments, she is a professor in the CIIS East-West Psychology graduate program, which was founded by Zen scholar and philosopher Alan Watts. For more than 25 years, Janis has been researching the global uses and practices of psychedelics in promoting healing and community development, deepening spiritual practices, and igniting mystical experiences. Her theoretical orientations include transpersonal and wellness therapy models; Buddhism and Eastern disciplines; phenomenology and existential philosophies. Her research and scholarly writing has focused on psychedelic therapy, entheogens, and mind-body wellness. She teaches graduate courses in quantitative and qualitative research methods, mindfulness, Buddhism and psychotherapy, spiritual counseling, and principles of healing. She serves on the board of the Holos Institute and maintains a private practice in Mill Valley. Her expertise puts her in an excellent position to create and nurture this innovative and timely certificate program.
David Presti, PhD, is Teaching Professor of Neurobiology, Psychology, and Cognitive Science at the University of California, Berkeley, where he has taught for 26 years. He also worked for more than a decade in the clinical treatment of addiction and post-traumatic stress at the Veterans Administration Medical Center in San Francisco, and since 2004 has been teaching neuroscience to Tibetan monastics in India, and most recently in Bhutan. He has been involved in shifting policy related to research and psychotherapy with psychedelics for 30 years. He has doctorates in molecular biology and biophysics from Caltech, and in clinical psychology from the University of Oregon.
William (Bill) Richards, STM, PhD, is a psychologist at the Johns Hopkins University School of Medicine, where he and his colleagues have pursued research with entheogens for the past 17 years, and a clinician in private practice in Baltimore. His graduate training in clinical psychology and the psychology of religion included studies at Yale University, the University of Göttingen, Andover-Newton Theological School, Brandeis University, and Catholic University. After encountering psilocybin research in Germany in 1963, he contributed to psychotherapy research with LSD, DPT, MDA, and psilocybin at the Maryland Psychiatric Research Center from 1967-1977. Columbia University Press published his seminal book, Sacred Knowledge: Psychedelics and Religious Experiences, in 2015.
Jan Edl Stein, MFT, is the clinical director of Holos Institute, a counseling center grounded in principles of eco-psychology, and a psychotherapist in private practice in San Francisco and Marin. Her theoretical orientation is in depth psychology, ecopsychology, and shamanism. She is interested in the integration of shamanic practices in clinical practice and the development of an eco-psychological framework that supports eco-resiliency and environmental awareness. She is also adjunct faculty at CIIS. Jan leads workshops and retreats that interweave meditation, active imagining, shamanic journeying and nature-based experiences. More information about Jan may be found at www.janedl.com.Y Press, 1985), The Holotropic Mind (Harper Collins, 1992), The Cosmic Game: Explorations of the Frontiers of Human Consciousness (SUNY Press, 1998), and Psychology of the Future: Lessons from Modern Consciousness Research (SUNY Press, 2000).
Berra Yazar-Klosinski, PhD, earned her doctorate in Molecular, Cell, and Developmental Biology from the University of California, Santa Cruz in 2010. She utilizes her scientific training and experience in for-profit pharmaceutical research to support MAPS' work to develop, design, and implement clinical psychedelic research in the U.S and beyond. She earned her B.S. in Biological Science from Stanford University in 2001, with an emphasis on the neurobiology of drugs. Prior to entering graduate school, Berra worked as a research associate with Geron Corporation screening for drugs that activate telomerase, and with Millennium Pharmaceuticals on Phase 1 clinical trials in patients with Acute Myeloid Leukemia. Berra joined MAPS in 2009 in order to work with an organization where profit would not dictate the agenda of scientific research. Since then, she has been actively involved in the ongoing Phase 2 clinical development of MDMA-assisted psychotherapy with an eye towards Phase 3 clinical trials.